nimotuzumab plus paclitaxel — Competitive Intelligence Brief

nimotuzumab plus paclitaxel (nimotuzumab plus paclitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody and taxane. Area: Oncology.

phase 3 Monoclonal antibody and taxane EGFR Oncology Small molecule

Target snapshot

nimotuzumab plus paclitaxel (nimotuzumab plus paclitaxel) — Biotech Pharmaceutical Co., Ltd.. Nimotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while paclitaxel is a taxane that inhibits cell division.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
nimotuzumab plus paclitaxel TARGET	nimotuzumab plus paclitaxel	Biotech Pharmaceutical Co., Ltd.	phase 3	Monoclonal antibody and taxane	EGFR
Rybrevant	AMIVANTAMAB	Johnson & Johnson	marketed		EGFR, MET	2021-01-01
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
PONATINIB HYDROCHLORIDE	PONATINIB HYDROCHLORIDE		marketed		ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3	2012-01-01
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
PAZOPANIB	PAZOPANIB		marketed	Kinase Inhibitor [EPC]	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ɑ, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody and taxane class)

1. Biotech Pharmaceutical Co., Ltd. · 1 drug in this class